updat fy sale estimate cc report
exhibit part due fx chang vs consensu
 in-lin w/ compani guidanc cc
ep estimate in-lin guidanc incl
fx exhibit forecast fy cc growth cvg
mitg rtg higher consensu expect
diabet rais pt investor focu shift mdt analyst
day june nyc
inform mdt analyst day
long term guidanc top-line segment ep growth
commit regard oper margin improv identif
specif lever rel appetit increas access ex-
us cash expect buy-back/dividend updat em strategi
expect develop market vs em growth rate pipelin market
approv time updat surgic robot trend less invas surgeri
pipelin like momentum competit respons db sacral
nerv prospect core spine peripher vascular pipelin anticip
thesi valuat risk continu see upsid share
price given view like enjoy organ msd sale growth
compound-annual-growth-rate modest margin expansion/shar buyback drive
hsd ep growth compound-annual-growth-rate pt base
rel valuat framework regress forward top-lin compound-annual-growth-rate
rel forward price-to-earnings med-tech stock analysi suggest
rel forward multipl slightli less
forward multipl enjoy last month
slightli revis month price target invok forward multipl
estim ep month henc given increas
cash access accru recent enact us tax reform
hope aggress vis-a-vi high growth earlier stage
acquisit could add spice stori given mdt unquestion
strength clinic trial regulatori commerci execut
continu pg
tr target
compani explicit commit margin expans unfett
access futur global cash encourag us elimin discount regress
suggest rel price-to-earnings previous appli target price risk pt includ
emerg market opacity/volatil greater expect matur product market weak failur
meet margin expans expect
page
exhibit fy revenu varianc vs consensu segment product categori
page
exhibit cont fy revenu varianc vs consensu segment product categori
page
page
page
period million ens ens net incom ex ni ex attribut analysisgross margin excl margin incl margin excl margin attribut analysi y/i cc pf pmr incom attribut medtron plc
world largest medic devic compani leadership across major market
compani four busi segment cardiac vascular minim invas technolog
restor therapi diabet headquart dublin ireland
continu see upsid share price given view like enjoy organ
msd sale growth compound-annual-growth-rate modest margin expansion/shar buyback drive hsd
ep growth compound-annual-growth-rate given increas cash access accru recent
enact us tax reform hope aggress vis-a-vi high growth earlier
stage acquisit could add spice stori given mdt unquestion strength clinic
trial regulatori commerci execut
valuat risk
pt base rel valuat framework regress forward top-lin
compound-annual-growth-rate rel forward price-to-earnings med-tech stock analysi suggest rel forward
multipl slightli less forward multipl enjoy
last month slightli revis month price target invok forward multipl
estim ep month henc compani explicit commit
margin expans unfett access futur global cash encourag
us elimin discount regress suggest rel price-to-earnings previous appli
target price risk pt includ emerg market opacity/volatil greater expect
matur product market weak failur meet margin expans expect
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
